Multiple Sclerosis Journal - October 2017 - 1533

journals.sagepub.com/home/msj

T26 (n = 34)

T52 (n = 34)

44.6 ± 7.1
0.79 ± 0.65
1.63 ± 0.63
1.58 ± 0.63
0.93 ± 0.41
1.87 ± 0.66

94.4 ± 16.3
15.5 ± 5.5
12.7 ± 4.9
21.6 ± 6.9
46.5 ± 10.6
21.5 ± 4.8
20.9 ± 6.5
4.2 ± 1.7
5.3 ± 0.7
54.3 ± 24.9
22.9 ± 32.4
64.9 ± 21.9
49.4 ± 14.6
40.4 ± 13.4
61.8 ± 17.1
65.7 ± 41.0
67.9 ± 14.6
0.4 ± 0.7
2.9 ± 2.1
3.1 ± 1.9
3.7 ± 1.7
1.6 ± 1.5

44.3 ± 7.9

0.80 ± 0.66
1.68 ± 0.64
1.61 ± 0.69
0.95 ± 0.44
1.89 ± 0.66

93.5 ± 17.7
15.5 ± 5.6
12.8 ± 4.9
20.9 ± 7.4

45.1 ± 11.7
21.2 ± 4.8
19.9 ± 7.6
4.0 ± 1.8
5.3 ± 0.8

53.9 ± 24.8
24.4 ± 33.8
65.3 ± 21.3
49.4 ± 14.0
41.1 ± 15.3
62.2 ± 16.9
68.3 ± 41.0
67.7 ± 15.5

0.4 ± 0.7
2.9 ± 2.2
3.1 ± 2.0
3.7 ± 1.7
1.7 ± 1.6

0.5 ± 0.7
3.0 ± 1.8
2.6 ± 2.2
4.1 ± 1.7
1.0 ± 1.0

55.3 ± 25.5
35.4 ± 41.1
63.9 ± 22.9
52.4 ± 13.8
39.7 ± 10.8
61.8 ± 14.3
70.4 ± 38.0
67.4 ± 18.6

42.9 ± 10.2
20.3 ± 4.2
18.6 ± 7.3
4.0 ± 1.2
5.2. ± 0.7

90.3 ± 13.3
14.4 ± 4.9
12.2 ± 3.9
20.2 ± 7.6

0.92 ± 0.55
1.57 ± 0.60
1.56 ± 0.59
1.19 ± 0.56
1.84 ± 0.80

43.4 ± 6.5

0.3 ± 0.6
2.6 ± 2.1
3.0 ± 2.2
3.6 ± 1.6
0.7 ± 1.1

53.7 ± 25.3
33.1 ± 35.2
67.9 ± 23.4
50.7 ± 14.0
45.3 ± 13.4
66.5 ± 20.8
65.7 ± 36.2
73.1 ± 14.1

41.2 ± 11.4
20.0 ± 5.2
17.4 ± 6.6
3.7 ± 1.3
5.3. ± 0.8

82.9 ± 15.6
13.5 ± 4.0
11.7 ± 3.9
19.5 ± 7.1

0.75 ± 0.60
1.62 ± 0.70
1.47 ± 0.52
1.05 ± 0.52
1.72 ± 0.65

38.2 ± 8.2

0.3 ± 0.7
2.9 ± 2.1
2.9 ± 2.3
3.7 ± 1.9
0.4 ± 0.7

55.7 ± 22.9
38.2 ± 43.2
63.7 ± 21.4
50.7 ± 12.7
43.5 ± 18.2
68.7 ± 17.2
73.5 ± 36.5
73.9 ± 16.3

40.4 ± 13.0
19.6 ± 5.6
17.2 ± 7.1
3.6 ± 1.5
5.3 ± 1.0

79.2 ± 20.3
12.5 ± 4.6
10.5 ± 3.9
19.4 ± 7.3

0.73 ± 0.58
1.52 ± 0.68
1.49 ± 0.63
1.11 ± 0.51
1.79 ± 0.67

36.8 ± 10.1

0.6 ± 0.9
3.8 ± 2.9
3.7 ± 2.8
3.9 ± 1.6
1.0 ± 1.6

55.4 ± 25.7
37.5 ± 37.6
61.3 ± 22.9
51.0 ± 15.4
44.0 ± 18.5
66.5 ± 21.3
76.5 ± 39.8
70.6 ± 18.7

41.4 ± 13.9
20.2 ± 6.3
17.5 ± 7.0
3.7 ± 1.8
5.3 ± 0.9

87.3 ± 20.4
13.9 ± 5.8
12.1 ± 4.1
20.4 ± 7.4

0.86 ± 0.74
1.59 ± 0.68
1.45 ± 0.70
1.12 ± 0.57
1.94 ± 0.83

40.9 ± 9.6

0.4 ± 0.7
2.5 ± 2.0
2.2 ± 2.2
3.4 ± 2.2
1.9 ± 1.4

59.2 ± 26.4
34.1 ± 37.4
67.3 ± 21.9
50.7 ± 13.1
40.5 ± 15.0
60.5 ± 22.5
62.1 ± 39.7
68.8 ± 14.7

42.7 ± 14.4
20.5 ± 5.7
18.2 ± 8.8
4.0 ± 1.9
5.1 ± 0.9

91.2 ± 15.7
15.0 ± 4.8
12.6 ± 4.9
20.0 ± 7.8

0.76 ± 0.69
1.54 ± 0.80
1.64 ± 0.63
1.06 ± 0.57
1.81 ± 0.88

43.6 ± 7.1

0.4 ± 0.7
2.4 ± 1.9
2.1 ± 2.0
3.4 ± 2.2
1.9 ± 1.5

59.1 ± 25.4
33.1 ± 38.6
67.5 ± 21.6
50.7 ± 13.3
39.4 ± 14.2
60.3 ± 21.3
60.0 ± 40.8
68.7 ± 14.9

43.8 ± 13.3
20.8 ± 4.9
18.9 ± 8.7
4.1 ± 1.7
5.2 ± 0.8

92.5 ± 15.5
15.1 ± 4.6
12.8 ± 4.8
20.8 ± 7.7

0.73 ± 0.64
1.56 ± 0.73
1.64 ± 0.53
1.05 ± 0.53
1.83 ± 0.86

43.9 ± 6.9

T-1 (n = 40)

0.5 ± 0.8
2.2 ± 1.9
2.2 ± 2.0
3.1 ± 2.0
0.7 ± 1.0

59.1 ± 26.8
35.3 ± 37.9
66.9 ± 23.1
48.7 ± 14.5
41.7 ± 14.3
65.4 ± 20.4
66.7 ± 41.2
68.5 ± 15.1

40.9 ± 14.1
20.1 ± 5.9
16.9 ± 8.6
3.9 ± 1.7
5.2 ± 0.9

86.9 ± 22.5
14.6 ± 5.4
12.3 ± 5.1
19.3 ± 8.7

0.77 ± 0.64
1.60 ± 0.69
1.55 ± 0.57
1.05 ± 0.49
1.89 ± 0.99

40.7 ± 9.8

T8 (n = 40)

0.4 ± 0.7
2.4 ± 2.2
1.8 ± 1.8
3.5 ± 2.0
0.5 ± 0.8

59.3 ± 26.8
42.6 ± 37.7
70.2 ± 20.9
48.9 ± 13.2
43.7 ± 14.7
67.2 ± 18.9
65.8 ± 36.4
72.6 ± 15.5

40.0 ± 14.5
19.8 ± 5.6
16.3 ± 8.9
3.9 ± 1.7
5.1. ± 0.7

83.2 ± 19.0
14.3 ± 5.2
12.0 ± 4.4
17.8 ± 7.7

0.79 ± 0.74
1.50 ± 0.74
1.50 ± 0.63
0.98 ± 0.54
1.69 ± 0.72

39.1 ± 8.5

T16 (n = 37)

0.4 ± 0.8
2.6 ± 2.0
2.1 ± 2.0
3.3 ± 2.1
0.6 ± 1.0

59.2 ± 24.6
51.4 ± 41.6
65.1 ± 23.7
47.9 ± 14.0
43.3 ± 17.8
67.6 ± 20.5
81.1 ± 35.6
71.6 ± 15.7

38.4 ± 15.9
18.6 ± 6.9
16.3 ± 9.1
3.5 ± 1.8
5.1. ± 0.9

86.0 ± 22.7
14.8 ± 6.1
12.0 ± 4.5
19.1 ± 8.6

0.80 ± 0.81
1.49 ± 0.81
1.51 ± 0.79
1.00 ± 0.57
1.80 ± 0.87

40.1 ± 9.4

T26 (n = 37)

0.5 ± 0.7
3.8 ± 3.3
2.3 ± 2.3
3.3 ± 1.8
0.9 ± 1.3

54.0 ± 28.5
37.1 ± 36.6
68.2 ± 23.5
49.6 ± 13.4
42.2 ± 17.6
65.7 ± 19.0
68.6 ± 41.9
69.5 ± 17.1

40.6 ± 16.7
20.0 ± 7.3
16.9 ± 9.5
3.6 ± 1.7
5.3 ± 0.9

90.8 ± 21.6
14.9 ± 5.5
13.0 ± 4.4
20.7 ± 7.8

0.83 ± 0.70
1.48 ± 0.81
1.63 ± 0.79
1.06 ± 0.55
1.78 ± 0.90

42.1 ± 8.9

T52 (n = 35)

T-1: baseline; T8, T16, T26 and T52: 8, 16, 26 and 52 weeks after randomization; ECM: energy conservation management; CIS20r: Checklist Individual Strength (fatigue domain max range 8-56); IPA: Impact on Participation and
Autonomy (max range 0-3); MFIS: Modified Fatigue Impact Scale; FSS: Fatigue Severity Scale; SF-36: health-related quality of life; RAP: Rehabilitation Activities Profile; SD: standard deviation.
Reported as mean ± SD.
*All randomized participants at baseline.

Primary outcomes
CIS20r
Fatigue
IPA
Autonomy indoors
Family role
Autonomy outdoors
Social life relations
Work and education
Secondary outcomes
CIS20r
Total
Motivation
Physical activity
Concentration
MFIS
Total
Physical
Cognitive
Psychosocial
FSS
SF-36
Physical function
Role physical
Body pain
General health
Vitality
Social function
Role emotional
Mental health
RAP
Communication
Mobility
Self-care
Occupation
Relationships

T16 (n = 34)

T-1* (n = 44)

T8 (n = 36)

T-1* (n = 42)

T-1 (n = 36)

Control group

ECM study group

Table 3. Observed data over time, specified per allocated study group.

LJM Blikman, J van Meeteren et al.

1533
https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
